Supraventricular and ventricular arrhythmia
Conditions
Interventions
None listed
Sponsors
University of Fukui Hospital Department of Cardiovascular Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who undergo cardiac electrophisiological study in Fukui University Hospital
Exclusion criteria
Exclusion criteria: Patients who do not give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of supraventricular and ventricular arrhythmia. Major adverse cardiac event (MACE), including cardiovascular death, non-fatal myocardial infarction, stroke, stent thrombosis, unstable angina and admission due to ischemic heart failure,implant of cardiovascular device, non--fatal arrhythmia | — |
Secondary
| Measure | Time frame |
|---|---|
| all death, malignancy, worsening of renal function, onset of diabetes, hypertension and dyslipidemia. Association with lipid profile, multimodalities and biomarkers. | — |
Countries
Japan
Contacts
Public ContactTetsuji Morishita
University of Fukui Hospital Department of Cardiovascular Medicine
Outcome results
None listed